Drug Maker Gets $26.7M to Fill Gap

Reed, Vita
May 2012
Orange County Business Journal;5/21/2012, Vol. 35 Issue 21, p3
The article reports on the funds that Aeolus Pharmaceuticals Inc. had raised worth 26.7 million dollars for covering the expenses on a biodefense drug compound development.


Related Articles

  • Learning from 9/11.  // BioWorld Today;9/8/2011, Vol. 22 Issue 174, p4 

    The article reports on the positive growth experienced by Mission Viejo, California-based biotechnology firm Aeolus Pharmaceuticals Inc. following the September 11, 2001 terrorist attacks. It notes that the firm entered the medical countermeasures (MCM) market after the National Institutes of...

  • Aeolus Pharmaceuticals Inc.  // BioWorld Today;10/11/2011, Vol. 22 Issue 197, p4 

    The article announces that Aeolus Pharmaceuticals Inc. received a 12.7 million dollars from the U.S. National Institutes of Health (NIH) to continue the development of AEOL10150 as medical countermeasure for sulfur mustard gas exposure.

  • FASTEST-GROWING PUBLIC COMPANIES: SMALL COMPANIES.  // Orange County Business Journal;11/4/2013, Vol. 36 Issue 44, p50 

    A chart is presented that lists the fastest-growing companies, small corporations categories in Orange County, California including Avanir Pharmaceuticals Inc., Pacific Health Care Organization Inc., Aeolus Pharmaceuticals Inc.

  • Majority Investors Sell Shares in Drug Hopeful Aeolus. Reed, Vita // Orange County Business Journal;3/6/2006, Vol. 29 Issue 10, p19 

    The article reports that stockholders of Aeolus Pharmaceuticals Inc., a drug developer primarily operating in San Diego, California, have planned to sell some of their 16 million dollar worth stock. U.S. Securities and Exchange Commission also announced that nearly 19 million dollar shares of...

  • Market Watch.  // Orange County Business Journal;4/22/2013, Vol. 36 Issue 16, p42 

    A table is presented which lists the market capitalization of several companies in California in April 2013 including the drug maker Aeolus Pharmaceuticals Inc. with an increase about seven percent, drug developer Peregrine Pharmaceuticals Inc. with an increase about six percent, and Plaza Bank...

  • Financings Roundup.  // BioWorld Today;8/16/2010, Vol. 21 Issue 157, p7 

    The article reports that Xmark Opportunity Partners LLC, via two of its institutional shareholders, issued 100 million U.S. dollars financing to Aeolus Pharmaceutical Inc. of Mission Viejo, California.

  • Stock Movers.  // BioWorld Today;1/4/2011, Vol. 22 Issue 2, p2 

    A chart is presented that shows changes in the stocks of biotechnology companies in the U.S. as of January 3, 2011 including Nasdaq Biotechnology, Aeolus Pharmaceuticals Inc. and Tengion Inc.

  • Other News To Note.  // BioWorld Today;6/4/2012, Vol. 23 Issue 107, p4 

    This section offers news briefs relating to the biopharmaceutical industry. A study of Aeolus Pharmaceuticals Inc.'s AEOL 10150 and Neupogen showed that treatment of the hematopoietic subsyndrome of acute radiation syndrome Neupogen aggravates radiation damage to the lung. The exclusive option...

  • Distressed Company Watch List. COLLINS, ALLISON // Mergers & Acquisitions Report;6/10/2013, Vol. 26 Issue 23, p22 

    A list of U.S. business enterprises that are facing financial challenges amidst their Securities and Exchange Commission (SEC) filings is presented including ACL Semiconductors Inc., Aeolus Pharmaceuticals Inc. and Alexza Pharmaceuticals Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics